CD8+ T-cell immunity orchestrated by iNKT cells

CD8(+) T cells belonging to the adaptive immune system play key roles in defending against viral infections and cancers. The current CD8(+) T cell-based immunotherapy has emerged as a superior therapeutic avenue for the eradication of tumor cells and long-term prevention of their recurrence in hematologic malignancies. It is believed that an effective adaptive immune response critically relies on the help of the innate compartment. Invariant natural killer T (iNKT) cells are innate-like T lymphocytes that have been considered some of the first cells to respond to infections and can secrete a large amount of diverse cytokines and chemokines to widely modulate the innate and adaptive immune responders. Like CD8(+) T cells, iNKT cells also play an important role in defense against intracellular pathogenic infections and cancers. In this review, we will discuss the CD8(+) T-cell immunity contributed by iNKT cells, including iNKT cell-mediated cross-priming and memory formation, and discuss recent advances in our understanding of the mechanisms underlying memory CD8(+) T-cell differentiation, as well as aging-induced impairment of T-cell immunity.

Automated summary

CD8(+) T cells from the adaptive immune system and iNKT cells from the innate-like T lymphocytes both play important roles in defending against infections and cancers. CD8(+) T cell-based immunotherapy is a promising approach for the eradication of tumor cells, and iNKT cells contribute to CD8(+) T cell immunity through cross-priming and memory formation. This review also discusses recent advances in understanding the mechanisms of memory CD8(+) T cell differentiation and aging-induced impairment of T cell immunity.